ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer
SSRN Electronic Journal
◽
10.2139/ssrn.3294124
◽
2018
◽
Author(s):
Qing Zhou
◽
Xiao-Qing Liu
◽
Pei Hu
◽
Jian-Ying Zhou
◽
Li Zhang
◽
...
Keyword(s):
Lung Cancer
◽
Kinase Inhibitor
◽
Phase 1
◽
Small Cell
◽
Chinese Patients
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Phase 1 Clinical Trial
◽
Egfr T790m
Download Full-text
Related Documents
Cited By
References
HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer
SSRN Electronic Journal
◽
10.2139/ssrn.3495608
◽
2019
◽
Author(s):
James Chih-Hsin Yang
◽
D. Ross Camidge
◽
Cheng-Ta Yang
◽
Jianying Zhou
◽
Renhua Guo
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Kinase Inhibitor
◽
Phase 1
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Previously Treated
◽
Egfr Mutant
Download Full-text
Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.9044
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. 9044-9044
◽
Cited By ~ 25
Author(s):
Daniel Shao-Weng Tan
◽
James Chih-Hsin Yang
◽
Natasha B. Leighl
◽
Gregory J. Riely
◽
Lecia V. Sequist
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Phase 1
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Phase 1 Study
◽
Egfr Tyrosine Kinase Inhibitor
Download Full-text
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
EBioMedicine
◽
10.1016/j.ebiom.2019.04.030
◽
2019
◽
Vol 43
◽
pp. 180-187
◽
Cited By ~ 6
Author(s):
Yi-Chen Zhang
◽
Zhi-Hong Chen
◽
Xu-Chao Zhang
◽
Chong-Rui Xu
◽
Hong-Hong Yan
◽
...
Keyword(s):
Lung Cancer
◽
Phase I
◽
Phase I Trial
◽
Kinase Inhibitor
◽
Resistance Mechanisms
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr T790m
Download Full-text
The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer
SSRN Electronic Journal
◽
10.2139/ssrn.3321505
◽
2019
◽
Author(s):
Yi-Chen Zhang
◽
Zhi-Hong Chen
◽
Xu-Chao Zhang
◽
Chong-Rui Xu
◽
Hong-Hong Yan
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr T790m
◽
Clinical Strategy
Download Full-text
A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-21-2595
◽
2021
◽
pp. clincanres.2595.2021
Author(s):
Qing Zhou
◽
Lin Wu
◽
Pei Hu
◽
Tongtong An
◽
Jianying Zhou
◽
...
Keyword(s):
Lung Cancer
◽
Tyrosine Kinase
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr T790m
Download Full-text
The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer
SSRN Electronic Journal
◽
10.2139/ssrn.3341474
◽
2019
◽
Author(s):
Yi-Chen Zhang
◽
Zhi-Hong Chen
◽
Xu-Chao Zhang
◽
Chong-Rui Xu
◽
Hong-Hong Yan
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr T790m
◽
Clinical Strategy
Download Full-text
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Annals of Oncology
◽
10.1093/annonc/mdz437.001
◽
2019
◽
Vol 30
◽
pp. ix158
◽
Cited By ~ 3
Author(s):
Y.-L. Wu
◽
T.S.K. Mok
◽
J.-Y. Han
◽
M.-J. Ahn
◽
A. Delmonte
◽
...
Keyword(s):
Lung Cancer
◽
Overall Survival
◽
Small Cell Lung Cancer
◽
Kinase Inhibitor
◽
Small Cell
◽
Phase Iii
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Phase Iii Study
◽
Egfr T790m
Download Full-text
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Investigational New Drugs
◽
10.1007/s10637-019-00732-4
◽
2019
◽
Vol 37
(6)
◽
pp. 1207-1217
Author(s):
Makoto Nishio
◽
Haruyasu Murakami
◽
Yuichiro Ohe
◽
Toyoaki Hida
◽
Hiroshi Sakai
◽
...
Keyword(s):
Lung Cancer
◽
Phase I Study
◽
Kinase Inhibitor
◽
Growth Factor Receptor
◽
Small Cell
◽
Egfr Mutations
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Epidermal Growth
Download Full-text
Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
10.1158/1538-7445.am2020-ct190
◽
2020
◽
Author(s):
Shun Lu
◽
Qiming Wang
◽
Guojun Zhang
◽
Xiaorong Dong
◽
Cheng-Ta Yang
◽
...
Keyword(s):
Kinase Inhibitor
◽
Phase Ii Study
◽
Locally Advanced
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Open Label
◽
Egfr Tyrosine Kinase Inhibitor
◽
The Third
◽
Egfr T790m
Download Full-text
Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non–Small Cell Lung Cancer
Molecular Cancer Therapeutics
◽
10.1158/1535-7163.mct-17-1033
◽
2018
◽
Vol 17
(4)
◽
pp. 740-750
◽
Cited By ~ 8
Author(s):
Toshiyuki Hirano
◽
Hiroyuki Yasuda
◽
Junko Hamamoto
◽
Shigenari Nukaga
◽
Keita Masuzawa
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Small Cell
◽
Third Generation
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Mutated
◽
Structural Characterizations
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close